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Infusion of sibling Marrow in a patient 
with purine Nucleoside phosphorylase 
Deficiency Leads to split Mixed Donor 
Chimerism and Normal Immunity
Laura Yeates, Mary A. Slatter and Andrew R. Gennery*
Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, United Kingdom
Purine nucleoside phosphorylase (PNP) deficiency, a rare autosomal recessive metabolic 
disease causes combined immunodeficiency and developmental delay, hypotonia, and 
spasticity. Patients present with recurrent infections associated with T-lymphocytopenia, 
characteristically presenting later than patients with classical severe combined immu-
nodeficiency (SCID). PNP, with adenosine deaminase (ADA), is part of the purine 
salvage pathway. The only curative therapy is hematopoietic stem cell transplantation. 
Myeloablative conditioning is recommended to prevent rejection caused by residual 
immune function. However, HLA-identical sibling stem cell infusions in ADA-SCID result 
in some donor stem cell engraftment and long-term thymopoiesis. We report a patient 
with PNP deficiency, who received HLA-identical sibling marrow without chemother-
apy because of disseminated cytomegalovirus (CMV) infection. The patient presented 
at 14 months of age following recurrent infections, from early infancy, with persistent 
irritability, developmental delay, and hypotonia. She had neutropenia, pan-lymphocyto-
penia, and hypogammaglobulinemia with low plasma urate and erythrocyte PNP activity. 
Diagnosis was confirmed with a homozygous mutation in PNP. The patient was viremic 
with CMV detected in blood and CSF by PCR. Dual antiviral therapy improved the clinical 
condition and reduced the viral load. In view of the disseminated CMV infection, the 
decision was made to infuse stem cells without any pre-conditioning chemotherapy. 
She received a matched sibling donor unconditioned stem cell infusion at 16 months of 
age. The post-transplant course was uneventful. Blood PCR became negative for CMV. 
Global hypotonia persisted, although with significant improvement in irritability. At 4 years 
of age and 29 months post-transplant, the patient demonstrated normal T-lymphocyte 
and natural killer cell numbers. Recent thymic emigrants represented 12% of the total 
T-lymphocyte population. Lymphocyte proliferative responses to phytohemagglutinin 
were normal. Memory and class-switched B-lymphocytes were present. Immunoglobulin 
replacement had been discontinued, and there were normal IgG responses to tetanus 
vaccine, Haemophilus influenzae type B and pneumococcal conjugate vaccine antigens. 
There was 93% donor T-lymphocytes, 20% donor B-lymphocytes, and 5% donor 
myeloid cells, indicative of some donor stem cell engraftment. There was no significant 
infection history despite regular nursery attendance. Height and weight were following 
the 50th centile. Split mixed donor chimerism has corrected the immunological defect.
Keywords: purine nucleoside phosphorylase, hematopoietic stem cell transplantation, sibling donor, 
unconditioned, immune reconstitution
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INtRoDUCtIoN
Purine nucleoside phosphorylase (PNP) deficiency (OMIM 
613179) is a rare autosomal recessive metabolic disease leading 
to combined immunodeficiency and neurological abnormali-
ties, which may include developmental delay, hypotonia, and 
spasticity (1, 2). Autoimmune manifestations are also reported, 
predominantly hematological cytopenias, but arthritis and 
systemic lupus erythematosus are reported (3). Patients present 
with predominantly T-lymphocytopenia, and the immuno-
logical presentation characteristically is later than patients 
with classical severe combined immunodeficiency (SCID) (4). 
Infectious complications include recurrent otitis media and 
lower respiratory tract infections—Pneumocystis jirovecii pneu-
monitis is a recognized presentation. Mucosal candidias is well 
documented, and patients can also present with disseminated 
BCG infection if they have been vaccinated. Susceptibility to 
viral infections including herpes viruses and polyoma JC virus 
is recognized (4–6).
Purine nucleoside phosphorylase is a ubiquitously expressed 
enzyme of the purine salvage pathway as is adenosine deami-
nase, deficiency of which also causes immunodeficiency. PNP is 
expressed at high levels in lymphocytes and causes the release of 
ribose phosphate by converting inosine to hypoxanthine, guano-
sine to guanine, and deoxyguanosine to guanine. PNP deficiency 
results in the accumulation of deoxyguanosine, which is converted 
to deoxyguanosine triphosphate (dGTP) by deoxycytidine kinase 
specific to lymphocytes. The excess of dGTP inhibits ribonu cleotide 
reductase and DNA synthesis, resulting in lymphocytotoxicity, 
affecting primarily T-lymphocytes possibly due to the prolifera-
tive stress to which thymocytes are subject during T-lymphocyte 
differentiation (7–9).
Neurological and infectious manifestations predominate in the 
clinical presentation, and patients usually present after the first 
year of life, in contra-distinction to adenosine deaminase-deficient 
patients. All patients have elevated inosine, deoxyinosine, guano-
sine, and deoxyguanosine in blood and urine. The blood urate 
is typically low. Patients demonstrate B- and T-lymphocytopenia 
(CD4  >  CD8) with poor proliferative responses, but normal 
numbers of NK lymphocytes. Panhypogammaglobulinemia is 
usually present, with absent vaccine-specific antibodies.
Supportive treatment in the form of immunoglobulin replace-
ment and antimicrobial prophylaxis should be initiated at diag-
nosis. However, the only curative therapy is hematopoietic stem 
cell transplantation (1). Some form of myeloablative conditioning 
regimen is generally recommended to counter the risk of rejec tion 
caused by residual immune function, which has been docu-
mented (10–13).
Long-term immune reconstitution in patients with SCID gen-
erally requires thymopoiesis to generate a normal, long-lasting 
naïve T-lymphocyte repertoire, best achieved if donor myeloid 
chimerism is present (14, 15). This, in turn, generally requires 
some chemotherapy to open the marrow niche to donor hemat-
opoietic stem cells. Uniquely, patients with adenosine deaminase-
deficient SCID can achieve partial donor stem cell engraftment 
following infusion of donor inoculum harvested from an HLA-
identical sibling (16). It is thought that “auto-conditioning” creates 
some marrow stem niches through the effects of toxic purine 
metabolites, thus enabling some donor hematopoietic stem cell 
engraftment. We report a patient with PNP deficiency, in whom 
we infused HLA-identical sibling marrow without chemotherapy 
because of disseminated cytomegalovirus (CMV) infection, and 
in whom split mixed donor chimerism has corrected the immu-
nological defect.
patIeNt aND MetHoDs
The patient, the second child of consanguineous Kurdish parents, 
born at term with an uneventful antenatal and postnatal course, 
presented at 14 months of age. She did not receive BCG vaccina-
tion but was otherwise fully vaccinated. There was a history of 
recurrent infections, from early infancy. She was persistently 
irritable, feverish, with developmental delay and hypotonia, with 
symptoms developing from 1 month of age. There was no family 
history of immunodeficiency or neurological problems.
Immunological investigations revealed neutropenia (0.18 ×   
109/l) pan-lymphocytopenia (Table  1) and hypogammaglobu-
linemia (IgG < 1.09 g/l, IgM < 0.05 g/l). The plasma urate was 
69 µmol/l (100–260). Erythrocyte PNP enzyme activity was low 
at 1,967 μmol/l (normal 3,000–7,000 μmol/l) and a homozygous 
mutation in PNP, exon 2, c.59A>C, p.20H>P was identified 
confirming PNP-deficient immunodeficiency.
The patient was discovered to be viremic with CMV 107  
copies/ml in blood by PCR and CMV in the cerebrospinal fluid.
She received dual therapy for disseminated CMV (with CMV 
encephalopathy) with gancilovir 10  mg/kg, increased from the 
initial dose of 5  mg/kg due to the high viral loads and CMV 
encephalopathy, and with foscarnet. Aspergillus fumigatus was 
isolated from broncho-alveolar secretions and treated with lipo-
somal amphotericin and voriconazole. She commenced regular 
immunoglobulin therapy and granulocyte colony stimulating 
factor to treat her neutropenia. Immunologically T-B-NK + SCID 
was confirmed.
With dual anti-viral therapy, she clinically improved, although 
remained very hypotonic and was irritable at times. Her CMV 
viral load in blood slowly reduced to 103 copies/ml at the time 
of transplant.
ResULts
An older, asymptomatic CMV positive HLA-identical sibling 
was chosen as a donor. In view of the disseminated CMV 
infection, the decision was made to infuse stem cells without 
any pre-conditioning chemotherapy. The parents were coun-
seled that this procedure would clear the CMV infection, but 
a further conditioned transplant would likely be required. She 
received a red cell depleted matched sibling donor uncondi-
tioned stem cell infusion at 16 months of age, with the aim of 
gaining peripheral T-lymphocyte engraftment and control of 
the CMV infection.
The inoculum contained 62 ml of bone marrow with 3.6 × 108/
kg nucleated cells, CD34 6.7 ×  106/kg, CD3 5.0 ×  107/kg, and 
CD19 2.2 × 107/kg without conditioning. She received ciclosporin 
as graft-versus-host disease (GvHD) prophylaxis from day −3.
tabLe 1 | Immunological parameters before and after hematopoietic stem cell transplantation.
pre-transplant post-transplant 1.92 years 3.42 years
D + 18 D + 53 D + 102 D + 203
Lymphocyte subsets
CD3 12 994 438 1,877 6,621 3,239 2,065
CD8 9 703 204 1,331 5,551 2,164 1,053
CD4 3 296 218 518 1,013 996 925
NK 52 40 52 122 283 147 139
CD19 9 26 9 72 146 106 92
DR+ (%) – 84 70 86 77 54 46
CD45RA/CD27+ – 20 – – 728 586 372
CD19+/CD27+/IgM− – – – – – 6% 9%
Chimerism (%)
Donor CD3 – 96 96 100 100 93 93
Donor CD19 – – – – – – 20
Donor CD15 – 5% 10 6 5 5 5
Immunoglobulins
IgG <0.3 9.4a 16.6a 7.2a 9.0a 3.4 4.7
IgA <0.04 <0.04 <0.04 0.15 0.43 0.37 0.55
IgM <0.05 <0.50 0.05 0.25 0.95 0.24 0.41
Tetanus 0.04 – – – – 0.18b 4.26c
Hib <0.01 – – – – 0.5b >9.0c
aOn IVIG.
bPre-vaccination, off IVIG replacement.
cPost-vaccination.
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The post-transplant course was largely uneventful. Grade 1 
skin GvHD responded to topical steroid treatment. Blood PCR 
became negative for CMV. Global hypotonia persisted, although 
there was a significant improvement in irritability. It was unclear 
how much the CMV infection contributed to the hypotonia, 
which is classically associated with PNP deficiency.
At 4 years of age and 29 months post-transplant the patient 
demonstrated full immune reconstitution. T-lymphocyte and 
natural killer cell numbers were normal. Recent thymic emi-
grants, denoted by CD4+/−CD45RA+CD27+ were present as 18% 
of the total T-lymphocyte population. Lymphocyte proliferative 
responses to phytohemagglutinin were normal. B-lymphocytes 
were slightly below the normal range, but memory and class-
switched B-lymphocytes present (Table  1). Immunoglobulin 
replacement had been discontinued. IgM was slightly below 
the normal range, but IgA and IgG were normal and there were 
normal IgG response to tetanus vaccine antigens, as well as to 
Haemophilus influenzae type B and the 13-valent pneumococ-
cal conjugate vaccine antigens. There was no evidence of CMV 
in blood by PCR. Autoantibodies were absent. Chimerism 
analysis demonstrated 93% donor T-lymphocytes, 20% donor 
B-lymphocytes and 5% donor myeloid cells, indicative of some 
donor stem cell engraftment. The plasma urate and erythrocyte 
PNP enzyme activity remained low at 64 and 1,967  µmol/l, 
respectively. There was no significant infection history despite 
regular nursery attendance. Height and weight were following 
the 50th centile.
Neurological assessment confirmed mild to moderate devel-
opmental delay, with global hypotonia. The patient was able 
to articulate few words due to pharyngeal hypotonia, but had 
normal comprehension. She was able to sit unaided, stand, and 
walk with support.
DIsCUssIoN
Purine nucleoside phosphorylase deficiency is an autosomal 
recessive metabolic disease, which typically causes immune dys-
function, spasticity, and developmental delay. The only curative 
treatment to date is hematopoietic stem cell transplantation. This 
typically follows a period of conditioning with chemotherapy, 
before infusion from a matched donor. A previous report 
of an unconditioned infusion from an HLA-matched non-
sibling family member in a patient with PNP deficiency reported 
donor T-lymphocyte engraftment with no B-lymphocyte (and 
presumably no stem cell) engraftment (17). Failure of stem cell 
engraftment may have been due to the inflammatory mileau 
caused by pre-existing BCG infection. Our case demonstrated 
some hematopoietic stem cell engraftment, which enabled 
enough T- and B-lymphocyte development to cure the underlying 
immu nodeficiency, given the selective advantage of lymphocytes 
with normal enzyme activity. As most stem cells remained of 
recipient origin, the plasma urate and erythrocyte enzyme activ-
ity was unaltered. The improvement in neurological status was 
most likely due to clearance of CMV, as there is no good evidence 
that hematopoietic stem cell transplantation can reverse the 
neurological sequalae in PNP deficiency, even with full donor 
chimerism.
Adenosine deaminase-deficient SCID patients have an 
improved outcome when undergoing unconditioned transplant 
compared to those whom have received myeloblative therapy 
(16). Unusually for patients receiving a stem cell infusion, these 
patients demonstrate some donor myeloid chimerism. The 
likely explanation for this is that there is a degree of “autologous 
conditioning” by the accumulated deoxyadenosinetrisphosphate 
(dATP), which causes inhibition of ribonucleotide reductase, 
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necessary for DNA replication and repair, as well as inducing 
caspase-mediated apoptosis through interaction with cyto-
plasmic apoptotic protease-activating factor 1 (Apaf-1) and 
cytochrome c. These cytotoxic effects may create some space 
in the stem cell niche to facilitate a degree of donor stem cell 
engraftment.
Purine nucleoside phosphorylase not only participates in the 
same purine salvage pathway as adenosine deaminase but also 
leads to an accumulation of dGTP rather than dATP. Like dATP, 
dGTP inhibits ribonucleotide reductase and DNA synthesis 
and repair. Additionally, there is experimental animal model 
evidence that the mitochondrial accumulation of dGTP initiates 
apoptosis by interference with the repair of mitochondrial DNA 
damage (18).
Thus, there is a hypothetical reason to suspect that patients 
with PNP deficiency may undergo a degree of autologous condi-
tioning, analogous to those patients with adenosine deaminase 
deficiency. While we based our decision to omit chemotherapy 
on clinical grounds, and had counseled the parents that a fully 
conditioned transplant following clearance of CMV may be 
required, nevertheless, our rationale was partly based on reason 
given that PNP and adenosine deaminase are part of the same 
purine salvage pathway.
The outcome of patients with adenosine deaminase 
deficiency who receive an infusion is superior to those who 
receive conditioning (16). PNP deficiency is less common than 
adenosine deaminase deficiency. Nevertheless, a multicenter 
study may be able to determine outcomes of patients who did 
or did not receive conditioning. Furthermore, it would be 
important to try and determine whether the degree of myeloid 
chimerism was important in determining neurological as well 
as immunological outcome. Of course, chemotherapy may 
have an adverse effect in terms of neurological development, 
particularly on a susceptible neurological substrate. Our case 
demonstrates at least that a sibling infusion can lead to tri-
lineage mixed donor chimerism and normal immunological 
function.
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